Last Update 02 Jun 26
Fair value Increased 0.019%LH: AI And New Diagnostics Collaborations Will Support Long Term Upside
Labcorp Holdings’ analyst price target has been adjusted slightly higher to approximately $310 per share as analysts refine their assumptions around the discount rate, revenue growth, profit margin and future P/E to reflect updated views on the company’s long-term earnings potential.
What's in the News
- Q1 2026 results show revenue of US$3.54b, up 5.8% year over year, and adjusted EPS of US$4.25, up 10.6%, with management raising full year 2026 revenue guidance to 5.0% to 6.1% growth and adjusted EPS guidance to US$17.70 to US$18.35 (source: Q1 2026 earnings release).
- Labcorp is leaning into AI and automation across its Diagnostics Laboratories and Biopharma Laboratory Services segments, citing benefits for diagnostic accuracy, efficiency and margins in the latest quarterly update (source: Q1 2026 earnings release).
- The company launched the MyLabcorp app, which uses AI to help patients interpret their lab results, access guideline based health content and manage appointments and billing in a HIPAA compliant setting (source: MyLabcorp launch announcement).
- Labcorp expanded its DPYD Genotyping test to cover all Tier 1 and Tier 2 variants recommended by the Association for Molecular Pathology, targeting safer use of fluoropyrimidine chemotherapy across multiple cancer types (source: DPYD test expansion announcement).
- New and expanded collaborations include work with the Children's Hospital of Philadelphia on pediatric diagnostics, with Illumina on precision oncology testing and with the Alliance for Clinical Trials in Oncology on a national colorectal cancer genetic testing trial (sources: collaboration announcements).
Valuation Changes
- Fair Value: Updated slightly higher from $310.06 to $310.12 per share, reflecting modest model refinements.
- Discount Rate: Adjusted slightly lower from 7.16% to 7.15%, implying a marginal change in the risk assumptions used in the analysis.
- Revenue Growth: Held broadly stable at 4.92%, indicating only a very small tweak to long term growth expectations.
- Net Profit Margin: Kept effectively unchanged at about 8.20%, with only a minor numerical adjustment in the model.
- Future P/E: Left almost flat at 22.20x, suggesting only a very small calibration to the long term valuation multiple.
Key Takeaways
- Strategic collaborations and acquisitions are expected to drive growth in high-growth therapeutic areas and partnerships with health systems.
- Introduction of innovative tests and tech enhancements is anticipated to improve margins and earnings, with initiatives offsetting rising personnel costs.
- Tariffs, regulatory changes, and competitive pressures could negatively affect Labcorp's revenue growth, margins, and earnings amidst global economic shifts and market challenges.
Catalysts
About Labcorp Holdings- Provides laboratory services.
- Labcorp's strategic collaborations and acquisitions, such as with Inspira Health and BioReference Health, are expected to drive revenue growth by expanding its presence in high-growth therapeutic areas like oncology and strengthening partnerships with health systems.
- The introduction of innovative tests in oncology, women's health, autoimmune disease, and neurology is anticipated to capture more test volume and outpace growth in the broader market, positively impacting revenue and earnings.
- The use of AI and technology innovations is enhancing operational efficiencies, improving margins through platforms like eClaim Assist and Labcorp Diagnostic Assistant.
- The Invitae integration is on track to be slightly accretive to earnings for the full year, contributing to overall margin expansion and earnings growth.
- Labcorp's LaunchPad initiative continues to produce expected cost savings, mitigating higher personnel costs and supporting margin expansion.
Labcorp Holdings Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Labcorp Holdings's revenue will grow by 4.9% annually over the next 3 years.
- Analysts assume that profit margins will increase from 6.7% today to 8.2% in 3 years time.
- Analysts expect earnings to reach $1.3 billion (and earnings per share of $17.56) by about June 2029, up from $941.5 million today. The analysts are largely in agreement about this estimate.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 22.4x on those 2029 earnings, which is the same as it is today today. This future PE is lower than the current PE for the US Healthcare industry at 23.2x.
- Analysts expect the number of shares outstanding to decline by 1.32% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.15%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- The impact of tariffs and regulatory changes could create cost pressures, affecting Labcorp Holdings' overall revenue growth and net margins, as they must either absorb costs or pass them on to customers.
- Ongoing shifts in the macroeconomic landscape, such as foreign exchange volatility and global economic conditions, could adversely impact Labcorp's revenue and earnings projections.
- The potential financial implications of PAMA (Protecting Access to Medicare Act) could lead to a $100 million impact on revenue, affecting net earnings if the legislation goes into effect without a delay or amendment.
- Competitive pressures in the Diagnostic Laboratories sector may affect pricing and margins, impacting Labcorp's revenue and net margins as contracts come up for renewal or new competitive bids are issued.
- The unpredictability and possible delays in clinical trial starts, due to regulatory review processes and biopharma R&D funding, could impact the Biopharma Laboratory Services segment's revenue and earnings.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $310.12 for Labcorp Holdings based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $340.0, and the most bearish reporting a price target of just $270.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $16.3 billion, earnings will come to $1.3 billion, and it would be trading on a PE ratio of 22.4x, assuming you use a discount rate of 7.2%.
- Given the current share price of $256.87, the analyst price target of $310.12 is 17.2% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Labcorp Holdings?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.